ClinicalTrials.gg
RecruitingNCT03684018Updated Jun 1, 2026

Two Dose Levels of Privigen in Pediatric CIDP

A Phase 4 interventional study of IgPro10 in Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), sponsored by CSL Behring. Recruiting at 9 sites in United States. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-06-01.

Primary conditionPolyradiculoneuropathy, Chronic Inflammatory DemyelinatingRegistry: PolyneuropathiesReclassifiedWhy we changed it
Registry
Polyneuropathies — the first condition term the registry derived for this study.
ClinicalTrials.gg
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Why
  1. The study's listed conditions name Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, a narrower term within Polyneuropathies.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by CSL Behring (part of CSL Limited) · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2019; still recruiting 7 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
2 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 55 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in United States — 20 open to participants now, 25 under way, 10 of them phase 3. Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States.

Planned enrollment
32nd of 42
30 · median 74
Started
2019
with 2 others
Phase 4
2 of 55
1 open now
Primary completion
2029-12
later than 21 of 24 live
Registered
19th of 55
by date
Lead sponsor
3 of 55
CSL Behring

Among the 55 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in United States, this one is the 32nd largest by planned enrollment of the 42 interventional ones that give a count, is one of 3 that started in 2019, is one of 2 in phase 4, reaches primary completion later than 21 of the 24 other live ones, and was the 19th registered.

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

137 studies on the registry are indexed under Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; 50 are open to participants now.

Browse Polyradiculoneuropathy, Chronic Inflammatory Demyelinating studies →

Open to participants now

20 of the 55 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 36 Polyradiculoneuropathy, Chronic Inflammatory Demyelinating studies recruiting now, 24 (67%) set no upper age limit and 9 (25%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.

This study: 2 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in United States, or all of them as a file.
02

Study summary

A randomized, open-label, prospective, multicenter study designed to investigate 2 dose levels in pediatric subjects 2 to ≤ 17 years of age with confirmed or possible CIDP, either previously exposed to IVIG treatment or unexposed to IVIG treatment

03

Conditions studied

  • Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Browse trials for

04

In context

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating Reclassified

137 studies on the registry are indexed under Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; 50 are open to participants now.

This study's planned enrollment of 30 is below the median of 39 across 84 interventional studies indexed under Polyradiculoneuropathy, Chronic Inflammatory Demyelinating.

Browse Polyradiculoneuropathy, Chronic Inflammatory Demyelinating studies →

Lead sponsor

CSL Behring is the lead sponsor of 145 studies on the registry; 17 are open to participants now.

Of its 24 completed or terminated interventional studies of FDA-regulated products, 17 (71%) have results posted.

First submitted after CSL Behring became part of CSL Limited.

Compared within Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Polyneuropathies. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • - Male or female subjects 2 to ≤ 17 years of age with confirmed or possible CIDP.

Exclusion criteria

Exclusion Criteria:

  • - Absence of CIDP symptoms
  • -History or family history of inherited neuropathy
  • -Diagnosed developmental delay or regression
  • -History of thrombotic episode
  • -Known or suspected to Privigen
  • -Known allergic or other severe reactions to blood products
  • -Female subject of either not using or not willing to use a medically reliable method of or not sexually abstinent during the study
  • -Pregnant or breastfeeding mother"
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

06

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    IgPro10 (dose level 1)

    Biological: IgPro10

  • Experimental
    IgPro10 (dose level 2)

    Biological: IgPro10

Interventions

  • BiologicalIgPro10

    Normal human immunoglobulin G administered intravenously

    Also known as: Privigen

07

What researchers measure

Primary outcomes

  1. Percentage (%) of subjects with CIDP relapse in the Randomized Phase by dose level

    CIDP relapse, defined as a clinical decline relative to the previous assessment as indicated by an increase in modified Rankin Scale (mRS) of ≥ 1 point, in the Randomized Phase

    Time frame: Approximately 24 weeks

Secondary outcomes

  1. Percentage of subjects with treatment emergent adverse events (TEAEs) by dose level

    Time frame: Approximately 56 weeks

  2. Rate of TEAEs per infusion

    Time frame: Approximately 56 weeks

  3. Rate of mild, moderate, and severe TEAEs per infusion by dose level

    Time frame: Approximately 56 weeks

  4. Percentage of subjects with serious TEAEs

    Time frame: Approximately 56 weeks

  5. Rate of serious TEAEs per infusion

    Time frame: Approximately 56 weeks

  6. Percentage of subjects with related TEAEs

    Time frame: Approximately 56 weeks

  7. Rate of related TEAEs per infusion

    Time frame: Approximately 56 weeks

  8. Percentage of subjects with CIDP relapse in the Dose Exploration Phase by dose level assigned in the Randomized Phase

    Time frame: Approximately 24 weeks

  9. Change in modified Rankin Scale (mRS) score from baseline in the Randomized Phase

    The mRS is a disability scale ranging from 0 (asymptomatic) to 6 (death)

    Time frame: Baseline and Approximately 24 weeks

  10. Percentage (%) of subjects with CIDP improvement in the Randomization Phase by dose level

    CIDP improvement in the Randomized Phase, defined as a decrease in mRS score ≥ 1 from previous visit

    Time frame: Approximately 24 weeks

  11. Percentage (%) of subjects with CIDP recovery in the Randomization Phase by dose level

    CIDP recovery in the Randomized Phase, defined as decrease in mRS score as comparedto baseline AND mRS score of 1 or 0 at end of Randomized Phase

    Time frame: Approximately 24 weeks

  12. Time to CIDP relapse in Randomized Phase by dose level

    Time frame: Approximately 24 weeks

  13. Percentage (%) of subjects with CIDP improvement in the Dose Exploration Phase (DEP) by dose level

    CIDP improvement in the Dose Exploration Phase, defined as decrease in mRS score ≥ 1 from baseline

    Time frame: Approximately 24 weeks

  14. Percentage (%) of subjects with CIDP recovery in the Dose Exploration Phase by dose level

    CIDP recovery in the Dose Exploration Phase, defined as decrease in mRS score compared to baseline AND mRS score of 1 or 0 at end of DEP

    Time frame: Approximately 24 weeks

  15. Time to CIDP Relapse in the Dose Exploration Phase by dose level

    Time frame: Approximately 24 weeks

08

Study locations

3 of 9 sites recruiting
09

References and documents

Publications

  • Bus SR, de Haan RJ, Vermeulen M, van Schaik IN, Eftimov F. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2024 Feb 14;2(2):CD001797. doi: 10.1002/14651858.CD001797.pub4. PubMed 38353301 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2019 (actual). Primary completion is estimated for Dec 2029, 129 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2018
First posted
Sep 25, 2018
StartActual
Feb 28, 2019
Primary completionEst.
Dec 20, 2029
CompletionEst.
Dec 20, 2029
Last update
Jun 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03684018
Lead sponsor
CSL Behring
Responsible party
Sponsor
First posted
Sep 25, 2018
Start date
Feb 28, 2019
Primary completion
Dec 20, 2029 (estimated)
Completion
Dec 20, 2029 (estimated)
Last update
Jun 1, 2026

Study contacts

Trial Registration Coordinator
Contact
clinicaltrials@cslbehring.com
6108784697 ext. +1
Study Director
study director · CSL Behring

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: IGPRO10

Start the discussion